The kallikrein system in retinal damage/protection

European Journal of Pharmacology

Volumn 749, Issue , 2015, Pages 161-163

  Masuda, Tomomi ^a   Shimazawa, Masamitsu ^a   Hara, Hideaki ^a  

^a GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Age related macular degeneration; Diabetic retinopathy; Glaucoma; Kallikrein; Ocular ischemic syndrome; Vascular endothelial growth factor

Indexed keywords

BRADYKININ; ENDOTHELIAL NITRIC OXIDE SYNTHASE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; PLASMA KALLIKREIN; PREKALLIKREIN; STAT3 PROTEIN; TISSUE KALLIKREIN; VASCULOTROPIN; VASCULOTROPIN 165; KALLIKREIN; VASCULOTROPIN A;

AGE RELATED MACULAR DEGENERATION; ANTIINFLAMMATORY ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BLOOD VESSEL PERMEABILITY; DIABETIC RETINOPATHY; EYE PROTECTION; GLAUCOMA; HUMAN; NONHUMAN; OCULAR ISCHEMIC SYNDROME; PROTEIN SYNTHESIS INHIBITION; RETINA INJURY; SUBRETINAL NEOVASCULARIZATION; ANIMAL; BLOOD; METABOLISM; RETINA DISEASE;

ANIMALS; HUMANS; KALLIKREINS; RETINAL DISEASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84922746542     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2014.10.007     Document Type: Article

References (30)

1. G.B. Arden Age-related macular degeneration J. Br. Menopause Soc. 12 2006 64 70
2. K.D. Bhoola, C.D. Figueroa, and K. Worthy Bioregulation of kinins: kallikreins, kininogens, and kininases Pharmacol. Rev. 44 1992 1 80
3. A. Clermont, T.J. Chilcote, T. Kita, J. Liu, P. Riva, S. Sinha, and E.P. Feener Plasma kallikrein mediates retinal vascular dysfunction and induces retinal thickening in diabetic rats Diabetes 60 2011 1590 1598
4. N. Ferrara Vascular endothelial growth factor: basic science and clinical progress Endocr. Rev. 25 2004 581 611
5. R.N. Frank Diabetic retinopathy N. Engl. J. Med. 350 2004 48 58
6. D. Fleischman, and R.R. Allingham The role of cerebrospinal fluid pressure in glaucoma and other ophthalmic diseases: a review Saudi J. Ophthalmol. 27 2013 97 106
7. J. Fukuhara, K. Noda, M. Murata, S. Namba, S. Kinoshita, Z. Dong, R. Ando, A. Lennikov, A. Kanda, and S. Ishida Tissue kallikrein attenuates choroidal neovascularization via cleavage of vascular endothelial growth factor Investig. Ophthalmol. Vis. Sci. 54 2013 274 279
8. C. Gilbert, and A. Foster Childhood blindness in the context of VISION 2020-the right to sight Bull. World Health Organ. 79 2001 227 232
9. D. Hanahan, and J. Folkman Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis Cell 86 1996 353 364
10. M. Hollborn, C. Stathopoulos, A. Steffen, P. Wiedemann, L. Kohen, and A. Bringmann Positive feedback regulation between MMP-9 and VEGF in human RPE cells Invest. Ophthalmol. Vis. Sci. 48 2007 4360 4367
11. M.S. Ip, I.U. Scott, G.C. Brown, M.M. Brown, A.C. Ho, S.S. Huang, and F.M. Recchia Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration: a report by the American Academy of Ophthalmology Ophthalmology 115 2008 1837 1846
12. N. Kato, Y. Hou, Z. Lu, C. Lu, H. Nagano, K. Suzuma, H. Takagi, and Y. Matsumoto Kallidinogenase normalizes retinal vasopermeability in streptozotocin-induced diabetic rats: potential roles of vascular endothelial growth factor and nitric oxide Eur. J. Pharmacol. 606 2009 187 190
13. L.S. Lim, P. Mitchell, J.M. Seddon, F.G. Holz, and T.Y. Wong Age-related macular degeneration Lancet 379 2012 1728 1738
14. J. Liu, A.C. Clermont, B.B. Gao, and E.P. Feener Intraocular hemorrhage causes retinal vascular dysfunction via plasma kallikrein Invest. Ophthalmol. Vis. Sci. 54 2013 1086 1094
15. A. Llobet, A. Gual, J. Palés, R. Barraquer, E. Tobías, and J.M. Nicolás Bradykinin decreases outflow facility in perfused anterior segments and induces shape changes in passaged BTM cells in vitro Invest. Ophthalmol. Vis. Sci. 40 1999 113 125
16. G. Malaguarnera, C. Gagliano, M. Giordano, S. Salomone, M. Vacante, C. Bucolo, F. Caraci, M. Reibaldi, F. Drago, T. Avitabile, and M. Motta Homocysteine serum levels in diabetic patients with non proliferative, proliferative and without retinopathy BioMed Res. Int. 2014 2014 191497
17. T. Masuda, M. Shimazawa, F. Ishizuka, S. Nakamura, K. Tsuruma, and H. Hara Tissue kallikrein (kallidinogenase) protects against retinal ischemic damage in mice Eur. J. Pharmacol. 738 2014 74 82
18. N. Nagai, Y. Oike, K. Izumi-Nagai, T. Koto, S. Satofuka, H. Shinoda, K. Noda, Y. Ozawa, M. Inoue, K. Tsubota, and S. Ishida Suppression of choroidal neovascularization by inhibiting angiotensin-converting enzyme: minimal role of bradykinin Invest. Ophthalmol. Vis. Sci. 48 2007 2321 2326
19. S. Nakamura, N. Morimoto, K. Tsuruma, H. Izuta, Y. Yasuda, N. Kato, T. Ikeda, M. Shimazawa, and H. Hara Tissue kallikrein inhibits retinal neovascularization via the cleavage of vascular endothelial growth factor-165 Arterioscler. Thromb. Vasc. Biol 31 2011 1041 1048
20. P.C. Papageorgiou, C.T. Chan, E.L. Yeo, P.H. Backx, and J.S. Floras Coagulation factor XIIa-kinin-mediated contribution to hypertension of chronic kidney disease J. Hypertens. 32 2014 1523 1533
21. M. Pathak, S.S. Wong, I. Dreveny, and J. Emsley Structure of plasma and tissue kallikreins Thromb. haemost. 110 2013 423 433
22. J.A. Phipps, A.C. Clermont, S. Sinha, T.J. Chilcote, S.E. Bursell, and E.P. Feener Plasma kallikrein mediates angiotensin II type 1 receptor-stimulated retinal vascular permeability Hypertension 53 2009 175 181
23. H.A. Quigley, and A.T. Broman The number of people with glaucoma worldwide in 2010 and 2020 Br. J. Ophthalmol. 90 2006 262 267
24. N.A. Sharif, and S.X. Xu Pharmacological characterization of bradykinin receptors coupled to phosphoinositide turnover in SV40-immortalized human trabecular meshwork cells Exp. Eye Res. 63 1996 631 637
25. N.A. Sharif, P. Katoli, D. Scott, L. Li, C. Kelly, S. Xu, S. Husain, C. Toris, and C. Crosson FR-190997, a nonpeptide bradykinin B2-receptor partial agonist, is a potent and efficacious intraocular pressure lowering agent in ocular hypertensive cynomolgus monkeys Drug Dev. Res. 75 2014 211 223
26. A. Sivalingam, G.C. Brown, and L.E. Magargal The ocular ischemic syndrome III. Visual prognosis and the effect of treatment Int. Ophthalmol. 15 1991 15 20
27. J.G. Webb, T.W. Shearer, P.W. Yates, Y.V. Mukhin, and C.E. Crosson Bradykinin enhancement of PGE2 signalling in bovine trabecular meshwork cells Exp. Eye Res. 76 2003 283 289
28. J.G. Webb The kallikrein/kinin system in ocular function J. Ocul. Pharmacol. Ther. 27 2011 539 543
29. L.H. Wei, M.L. Kuo, C.A. Chen, C.H. Chou, K.B. Lai, C.N. Lee, and C.Y. Hsieh Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway Oncogene 22 2003 1517 1527
30. C.F. Xia, H. Yin, Y.Y. Yao, C.V. Borlongan, L. Chao, and J. Chao Kallikrein protects against ischemic stroke by inhibiting apoptosis and inflammation and promoting angiogenesis and neurogenesis Human Gene Ther. 17 2006 206 219